Joo Hang Kim

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

Tudor–Eliade Ciuleanu, Thomas Brodowicz, Christoph Zielinski et al. · The Lancet · 2009 · 1.1K citations · Full text

Non-small-cell Lung Cancer, Medicine, Cancer Management +6

Activation of IL-6R/JAK1/STAT3 Signaling Induces <i>De Novo</i> Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation

Sun Mi Kim, Oh-Joon Kwon, Yun Hong et al. · Molecular Cancer Therapeutics · 2012 · 194 citations · Full text

Irreversible Egfr Inhibitors, Cell Signaling, T790m Resistance Mutation +13

Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy

Dae Ho Lee, Keunchil Park, Joo Hang Kim et al. · Clinical Cancer Research · 2010 · 176 citations · Full text

Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer

Hye Ryun Kim, Dae Joon Kim, Dae Ryong Kang et al. · Journal of Clinical Oncology · 2012 · 165 citations · Full text